News
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for ...
Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Novo Nordisk trades for ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...
10hon MSN
Emily Field, Barclacys head of European pharmaceuticals equity research, joins 'Squawk Box' to discuss Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback